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Abstract: microRNAs (miRNAs) bind to mRNAs and inhibit their expression through
post-transcriptionally regulating gene expression. Here, we elaborate upon the concise summary of
the role of miRNAs in carcinogenesis with specific attention to precursor respiratory pathogenesis
caused by cigarette smoke modulation of these miRNAs. We review how miRNAs are implicated
in cigarette-smoke-driven mechanisms, such as epithelial to mesenchymal transition, autophagy
modulation, and lung ageing, which are important in the development of chronic obstructive
pulmonary disease and potential progression to lung cancer. Extracellular vesicles are key to
inter-cellular communication and sharing of miRNAs. A deeper understanding of the role of miRNAs
in chronic respiratory disease and their use as clinical biomarkers has great potential. Therapeutic
targeting of miRNAs may significantly benefit the prevention of cancer progression.
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The recent review article from Fujii et al. provides a concise and comprehensive summary of
research uncovering the role of microRNAs (miRNAs) in carcinogenesis with specific attention on
cigarette smoke modulation of these miRNAs [1]. In short, miRNAs bind to mRNAs and inhibit their
expression through post-transcriptionally regulating gene expression [2]. Cigarette smoke regulates the
expression of various miRNAs (e.g., epigenetic repression of miR-487b, reduced expression of mir-218),
promoting smoking-induced carcinogenesis either through the silencing of anticancer molecules or
upregulation of genes involved in lung cancer [3,4].
We are particularly interested in this process involving cigarette-smoke-driven lung carcinogenesis
and applaud the writers of this review on their excellent summary of the findings on miRNAs and
the development of lung cancer. Of note, tobacco cigarette smoking is the primary cause of chronic
obstructive pulmonary disease (COPD) and is expected to be the third leading cause of global mortality
by 2030, with COPD closely associated with the development of lung cancer [5]. The risk of developing
lung cancer is far more significant for those suffering from COPD who smoke than those without [6],
and along with underlying pathophysiological changes, COPD is most likely to be the strongest
driver of lung cancer [5]. In the United States, approximately 80% of lung-cancer-related deaths
were linked to smoking in 2012 [7]. Repeated exposure to cigarette smoke can also result in chronic
stress from free radicals [8,9] and cellular reprogramming events such as epithelial to mesenchymal
transition (EMT), which is highly active in both COPD and lung cancer patients [10–17]. Fujii et al.
showed the promotion of EMT via miR-331-3p, contributing to the progression of prostate cancer [18].
miR-331-3p is over-expressed in asbestos-related lung cancer samples [19]. miR-200 is associated
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with tumour suppression through the binding to zinc finger E-box-binding homeobox 1 (ZEB1) and
E-cadherin transcriptional repressor, resulting in the inhibition of EMT [20]. Lung cancer cell metastasis
has been shown to be regulated by miR-200 expression [21]. Activation of the autophagy proteins
and overall elevation of autophagy upon cigarette smoke stimulation carries significance in COPD
pathogenesis and the potential progression to lung cancer [22,23]. miR-155 has been shown to be
involved in the inhibition of autophagy, boosting the immune system, recruitment of tumour-infiltrating
lymphocytes, and improving chemosensitivity [24]. We are witnessing a gradual decline in global
cigarette smoking prevalence [25]. However, the rise in electronic nicotine delivery systems (ENDS)
is concerning [26]. Exposure to electronic cigarette vapour has been shown to induce systemic
inflammation and multi-organ fibrosis in mice [27], with short-term exposure linked to an increase in
angiogenesis [28]. We highlight that electronic cigarette exposure also affects the lungs and may have
a potential carcinogenic nature [29,30]. Nitrosamines were recently identified in electronic cigarette
vapour, which implicates that inhalation could potentiate in lung cancer via induced DNA damage [31].
Fujii et al. further illustrates the potential role of smoking-related miRNAs in ageing and their
susceptibility to lung and other forms of cancer [1]. Cellular ageing is known to cause tissue metabolic
homeostasis imbalances, tilting toward a more catabolic mechanism, which leads to progressive
declines in structure and function, until their final demise [32]. Several factors define the progression
of ageing including increased genomic instability/mutation, increase in telomerase activity vis-à-vis
a decrease in telomere size, epigenetics, dysregulation of autophagy, increase urea cycle activity,
increased cellular senescence and associated inflammation, apoptosis, and functional alteration in cell
communication [33]. The genome-wide assessment has confirmed that decrease in miRNAs occurs
during ageing and these changes, could increase the risk in the tumorigenic activity. For example,
downregulation of cancer-associated miRNAs, such as miR-103, -107, -128, and -221, was observed
in an aged compared to a younger population, and repression of these miRNA was associated with
increased cancer risk [34]. In the younger smoking population and COPD patients, lung ageing could
play a crucial role in the overall dynamics associated with disease progression and hence dysregulation
in miRNA is likely to be symptomatic in these patient populations.
Oxidants and toxins present in tobacco smoking induce considerable DNA damage, which
increases the DNA damage response (DDR), causing pathophysiology ageing disorders such as
cardiovascular disease (CVD) and cancer, which are characteristic comorbidities often diagnosed
within the COPD patient population [5]. Suppression of miRNA-126 expression is known to play an
essential role in the development of CVD and several types of cancer, including lung cancer. miRNA126
expression in epithelial and endothelial cells from smokers and COPD patients were reduced, which
was also associated with increased DDR, cellular senescence, and lung tissue dysfunction [35]. A more
recent genome-wide study in the whole blood of COPD patients identified two blood-born microRNAs
(miR-150-5p and miR-320b) that could efficiently predict patient survival. Higher expression of
miR-150-5p showed increase survivability in COPD patients compared with patients with the lowest
expression of the miRNA [36].
Inter-cell communication occurs via the transfer of extracellular vesicles (EVs) [37]. Based on the
size and origin, EVs are distinguished into exosomes, ectosomes, and apoptotic bodies. In physiological
conditions, they play a crucial role in maintaining tissue homeostasis. Exosomes are typically generated
by inward budding of the membrane (endocytosis), subsequently form multivesicular bodies, and are
released by exocytosis [38]. Ectosomes are formed by outward blebbing from the plasma membrane
and are released by proteolytic cleavage from the cell surface. Both exosomes and ectosomes play
differential roles [38]: exosomes carry vital cellular information in the form of embedded functional
proteins, RNA, and DNA; ectosomes carry cell surface receptors and ligands that could externally
activate cells by effectively inducing cellular signalling mechanisms.
EVs are also known to contain an array of miRNAs that are internalised or transferred into
neighbouring cells and can produce similar phenotypic effects as parent cells [37]. Such EV-based
cellular transformation has been demonstrated in an invitro co-culture study using human bronchial
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epithelial cells (HBEC) and a lung fibroblast model of COPD. Cigarette smoke extract induced
HBEC-cells-derived exosomes carrying miRNA-210 was found to promote the transformation of the
lung fibroblast into its more active and aggressive form, myofibroblast [39]. miRNA210 significantly
decreased autophagy induction in COPD patients by silencing ATG7, an autophagy regulator. Inhibition
of ATG7 was also observed to transform lung fibroblast to myofibroblast [39]. The abnormal increase
in myofibroblast number has been widely implicated in pathological lung tissue remodelling via the
accumulation of extracellular matrix proteins such as collagen and fibronectin [40].
Fujii et al. further explored the specific role of miRNA expression in driving various mechanisms
associated with cancer developments [41]. miRNAs are now known to influence cancer in two ways:
by regulating the expression of protein-coding oncogenes and tumour suppressors, such as ALK, TP53,
VEGF family, E-cadherin; or by acting as oncogenes and tumour suppressors, such as the let-7, miR-21,
and miR34 family [42]. For example, miR-126 is a cancer-suppressive miRNA that can decrease the
expression of vascular endothelial growth factor-A (VEGF-A). VEGF up-regulation is observed in
many carcinomas including lung carcinoma, and this primarily occursvia the suppression of miR-126
expression [43]. Cigarette smoke exposure is a major factor that affects the expression of miRNAs,
especially during the early stage. Tumour suppressor miRNAs are mainly downregulated due to
cigarette smoke exposure [41]. Smoking could also induce single nucleotide polymorphism (SNP)
mutations in miRNA genes, which lead to their downregulation [44]. However, one study showed
that two miRNAs, mir-138 and let-7c, were significantly downregulated in non-smokers with lung
cancer. Another study similarly reported that reduced let-7 expression occurred early during lung
carcinogenesis [45]. miRNAs have been proven to be most efficient in assisting with identifying tumour
histology and predicting patient outcomes [46]. For instance, studies reported that miRNA-486-5p
is downregulated and correlated with ankyrin1 (ANK1) expression in non-small cell lung cancer
(NSCLC) [47]. The study also found that ANK1 methylation is more prevalent in adenocarcinoma
compared with squamous cell carcinoma.
Reduced miR-486-5p expression actively contributes to lung cancer progression. Thus, it could be
potentially used as a prognostic biomarker that could be reliably detected in easily accessible samples
such as serum and sputum [48–50]. miRNAs have also been shown to play a crucial role in lung cancer
chemoresistance by affecting autophagic flux and expression of both programmed cell death-1 (PD-1)
and ligand PD-L1 (PD-L1) through post-transcriptional regulation [51–53]. PD-1 plays a crucial role in
chemoresistance by suppressing the immune response during lung tumorigenesis [54,55]. Specifically,
PD-1, as a cell surface receptor present on T cells and pro-B cells, binds its ligand PD-L1 and PD-L2
and triggers a net immunosuppressive effect that allows tumour cells to evade immune detection
and destruction [56]. Accumulating evidence suggests that miRNAs can modulate several molecular
mechanisms involved in tumour progression, autophagy activation, and metastasis. The clinical
benefit of these mechanisms will be using these miRNA and other prognostic miRNA signatures as
disease fingerprints and implementing them as potential early detection biomarkers, complementing
concurrent lung cancer screening [51–53].
As our understanding grows in the area of cigarette-smoke-induced disease carcinogenesis,
several other potentially deadly lifestyles have emerged, which could further contribute to disease
vulnerability in the human population. We think a deeper understanding of the role of miRNAs in
chronic lung pathogenesis will prove ideal in the fight against cancer progression.
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